Literature DB >> 25485595

Nonsense-mediated decay in genetic disease: friend or foe?

Jake N Miller1, David A Pearce2.   

Abstract

Eukaryotic cells utilize various RNA quality control mechanisms to ensure high fidelity of gene expression, thus protecting against the accumulation of nonfunctional RNA and the subsequent production of abnormal peptides. Messenger RNAs (mRNAs) are largely responsible for protein production, and mRNA quality control is particularly important for protecting the cell against the downstream effects of genetic mutations. Nonsense-mediated decay (NMD) is an evolutionarily conserved mRNA quality control system in all eukaryotes that degrades transcripts containing premature termination codons (PTCs). By degrading these aberrant transcripts, NMD acts to prevent the production of truncated proteins that could otherwise harm the cell through various insults, such as dominant negative effects or the ER stress response. Although NMD functions to protect the cell against the deleterious effects of aberrant mRNA, there is a growing body of evidence that mutation-, codon-, gene-, cell-, and tissue-specific differences in NMD efficiency can alter the underlying pathology of genetic disease. In addition, the protective role that NMD plays in genetic disease can undermine current therapeutic strategies aimed at increasing the production of full-length functional protein from genes harboring nonsense mutations. Here, we review the normal function of this RNA surveillance pathway and how it is regulated, provide current evidence for the role that it plays in modulating genetic disease phenotypes, and how NMD can be used as a therapeutic target.
Copyright © 2014 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Genetic disease; Nonsense suppression; Nonsense-mediated decay; Read-through

Mesh:

Substances:

Year:  2014        PMID: 25485595      PMCID: PMC4260155          DOI: 10.1016/j.mrrev.2014.05.001

Source DB:  PubMed          Journal:  Mutat Res Rev Mutat Res        ISSN: 1383-5742            Impact factor:   5.657


  172 in total

1.  Altered microRNA regulation in Huntington's disease models.

Authors:  Soon-Tae Lee; Kon Chu; Woo-Seok Im; Hye-Jin Yoon; Ji-Yeon Im; Jung-Eun Park; Ki-Ho Park; Keun-Hwa Jung; Sang Kun Lee; Manho Kim; Jae-Kyu Roh
Journal:  Exp Neurol       Date:  2010-10-28       Impact factor: 5.330

2.  PTC124-mediated translational readthrough of a nonsense mutation causing Usher syndrome type 1C.

Authors:  T Goldmann; N Overlack; U Wolfrum; K Nagel-Wolfrum
Journal:  Hum Gene Ther       Date:  2011-03-25       Impact factor: 5.695

3.  Perturbation of thymocyte development in nonsense-mediated decay (NMD)-deficient mice.

Authors:  Pamela A Frischmeyer-Guerrerio; Robert A Montgomery; Daniel S Warren; Sara K Cooke; Johannes Lutz; Christopher J Sonnenday; Anthony L Guerrerio; Harry C Dietz
Journal:  Proc Natl Acad Sci U S A       Date:  2011-06-13       Impact factor: 11.205

4.  RNA homeostasis governed by cell type-specific and branched feedback loops acting on NMD.

Authors:  Lulu Huang; Chih-Hong Lou; Waikin Chan; Eleen Y Shum; Ada Shao; Erica Stone; Rachid Karam; Hye-Won Song; Miles F Wilkinson
Journal:  Mol Cell       Date:  2011-09-16       Impact factor: 17.970

Review 5.  Nonsense-mediated mRNA decay (NMD) in animal embryogenesis: to die or not to die, that is the question.

Authors:  Jungwook Hwang; Lynne E Maquat
Journal:  Curr Opin Genet Dev       Date:  2011-08       Impact factor: 5.578

6.  PTC124 improves readthrough and increases enzymatic activity of the CPT1A R160X nonsense mutation.

Authors:  Lu Tan; Srinivas B Narayan; Jie Chen; Gail Ditewig Meyers; Michael J Bennett
Journal:  J Inherit Metab Dis       Date:  2011-01-21       Impact factor: 4.982

7.  Nonsense suppressor therapies rescue peroxisome lipid metabolism and assembly in cells from patients with specific PEX gene mutations.

Authors:  Patricia K Dranchak; Erminia Di Pietro; Ann Snowden; Nathan Oesch; Nancy E Braverman; Steven J Steinberg; Joseph G Hacia
Journal:  J Cell Biochem       Date:  2011-05       Impact factor: 4.429

8.  Identification of a microRNA that activates gene expression by repressing nonsense-mediated RNA decay.

Authors:  Ivone G Bruno; Rachid Karam; Lulu Huang; Anjana Bhardwaj; Chih H Lou; Eleen Y Shum; Hye-Won Song; Mark A Corbett; Wesley D Gifford; Jozef Gecz; Samuel L Pfaff; Miles F Wilkinson
Journal:  Mol Cell       Date:  2011-05-20       Impact factor: 17.970

9.  Readthrough of nonsense mutations in Rett syndrome: evaluation of novel aminoglycosides and generation of a new mouse model.

Authors:  Cornelia Brendel; Valery Belakhov; Hauke Werner; Eike Wegener; Jutta Gärtner; Igor Nudelman; Timor Baasov; Peter Huppke
Journal:  J Mol Med (Berl)       Date:  2010-12-01       Impact factor: 4.599

10.  Ex vivo treatment with a novel synthetic aminoglycoside NB54 in primary fibroblasts from Rett syndrome patients suppresses MECP2 nonsense mutations.

Authors:  Manuela Vecsler; Bruria Ben Zeev; Igor Nudelman; Yair Anikster; Amos J Simon; Ninette Amariglio; Gideon Rechavi; Timor Baasov; Eva Gak
Journal:  PLoS One       Date:  2011-06-13       Impact factor: 3.240

View more
  80 in total

Review 1.  Nonsense-mediated mRNA decay: an intricate machinery that shapes transcriptomes.

Authors:  Søren Lykke-Andersen; Torben Heick Jensen
Journal:  Nat Rev Mol Cell Biol       Date:  2015-09-23       Impact factor: 94.444

Review 2.  Genomics of Immune Diseases and New Therapies.

Authors:  Michael Lenardo; Bernice Lo; Carrie L Lucas
Journal:  Annu Rev Immunol       Date:  2015-12-23       Impact factor: 28.527

3.  FAM92A Underlies Nonsyndromic Postaxial Polydactyly in Humans and an Abnormal Limb and Digit Skeletal Phenotype in Mice.

Authors:  Isabelle Schrauwen; Arnaud Pj Giese; Abdul Aziz; David Tino Lafont; Imen Chakchouk; Regie Lyn P Santos-Cortez; Kwanghyuk Lee; Anushree Acharya; Falak Sher Khan; Asmat Ullah; Deborah A Nickerson; Michael J Bamshad; Ghazanfar Ali; Saima Riazuddin; Muhammad Ansar; Wasim Ahmad; Zubair M Ahmed; Suzanne M Leal
Journal:  J Bone Miner Res       Date:  2018-11-05       Impact factor: 6.741

4.  A Young Woman With Recurrent Gestational Hypercalcemia and Acute Pancreatitis Caused by CYP24A1 Deficiency.

Authors:  Gina N Woods; Alec Saitman; Hanlin Gao; Nigel J Clarke; Robert L Fitzgerald; Nai-Wen Chi
Journal:  J Bone Miner Res       Date:  2016-05-06       Impact factor: 6.741

5.  Osteogenesis imperfecta mutations in plastin 3 lead to impaired calcium regulation of actin bundling.

Authors:  Christopher L Schwebach; Elena Kudryashova; Weili Zheng; Matthew Orchard; Harper Smith; Lucas A Runyan; Edward H Egelman; Dmitri S Kudryashov
Journal:  Bone Res       Date:  2020-05-22       Impact factor: 13.567

Review 6.  mRNA Editing, Processing and Quality Control in Caenorhabditis elegans.

Authors:  Joshua A Arribere; Hidehito Kuroyanagi; Heather A Hundley
Journal:  Genetics       Date:  2020-07       Impact factor: 4.562

Review 7.  Nonsense-Mediated mRNA Decay: Degradation of Defective Transcripts Is Only Part of the Story.

Authors:  Feng He; Allan Jacobson
Journal:  Annu Rev Genet       Date:  2015-10-02       Impact factor: 16.830

8.  New variants in Spanish Niemann-Pick type c disease patients.

Authors:  Laura López de Frutos; Jorge J Cebolla; Luis Aldámiz-Echevarría; Ángela de la Vega; Sinziana Stanescu; Carlos Lahoz; Pilar Irún; Pilar Giraldo
Journal:  Mol Biol Rep       Date:  2020-02-14       Impact factor: 2.316

9.  Hypoplastic AI with Highly Variable Expressivity Caused by ENAM Mutations.

Authors:  M Koruyucu; J Kang; Y J Kim; F Seymen; Y Kasimoglu; Z H Lee; T J Shin; H K Hyun; Y J Kim; S H Lee; J C C Hu; J P Simmer; J W Kim
Journal:  J Dent Res       Date:  2018-03-19       Impact factor: 6.116

10.  Blasticidin S inhibits mammalian translation and enhances production of protein encoded by nonsense mRNA.

Authors:  Kyle T Powers; Flint Stevenson-Jones; Sathish K N Yadav; Beate Amthor; Joshua C Bufton; Ufuk Borucu; Dakang Shen; Jonas P Becker; Daria Lavysh; Matthias W Hentze; Andreas E Kulozik; Gabriele Neu-Yilik; Christiane Schaffitzel
Journal:  Nucleic Acids Res       Date:  2021-07-21       Impact factor: 16.971

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.